Literature DB >> 16169933

MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability.

K B Niendorf1, W Goggins, G Yang, K Y Tsai, M Shennan, D W Bell, A J Sober, D Hogg, H Tsao.   

Abstract

BACKGROUND: Heritable alterations in CDKN2A account for a subset of familial melanoma cases although no robust method exists to identify those at risk of being a mutation carrier.
METHODS: We set out to construct a model for estimating CDKN2A mutation carrier probability using a cohort of 116 consecutive familial cutaneous melanoma patients evaluated at Massachusetts General Hospital Pigmented Lesion Center between April 2001 and September 2004. Germline CDKN2A and CDK4 status on the familial melanoma cases and clinical features associated with mutational status were then used to build a multiple logistic regression model to predict carrier probability and performance of model on external validation.
RESULTS: From the 116 kindreds prone to melanoma in the Boston area, 13 CDKN2A mutation carriers were identified and 12 were subsequently used in the modeling. Proband age at diagnosis, number of proband primaries, and number of additional family primaries were most closely associated with germline mutations. The estimated probability of the proband being a mutation carrier based on the logistic regression model (MELPREDICT) is given by e(L)/(1 + e(L) where L = 1.99+[0.92x(no. of proband primaries)]+[0.74x(no. of additional family primaries)]-[2.11xln(age)]. The mean estimated probabilities for subjects in the Boston dataset were 55.4% and 5.1% for the mutation carriers and non-carriers respectively. In a receiver operator characteristic analysis, the area under the curve was 0.881 (95% confidence interval 0.739 to 1.000) for the Boston model set (n = 116) and 0.803 (0.729 to 0.877) for an external Toronto hereditary melanoma cohort (n = 143).
CONCLUSIONS: These results represent the first-iteration logistic regression model to approximate CDKN2A carrier probability. Validation of this model with an external dataset revealed relatively robust performance.

Entities:  

Mesh:

Year:  2005        PMID: 16169933      PMCID: PMC2564534          DOI: 10.1136/jmg.2005.032441

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  22 in total

1.  Genetic testing for melanoma.

Authors:  Richard Kefford; Julia Newton Bishop; Margaret Tucker; Brigitte Bressac-de Paillerets; Giovanna Bianchi-Scarrá; Wilma Bergman; Alisa Goldstein; Susana Puig; Rona Mackie; David Elder; Johan Hansson; Nicholas Hayward; David Hogg; Håkan Olsson
Journal:  Lancet Oncol       Date:  2002-11       Impact factor: 41.316

Review 2.  Genetics of melanoma predisposition.

Authors:  Nicholas K Hayward
Journal:  Oncogene       Date:  2003-05-19       Impact factor: 9.867

3.  Localization of a novel melanoma susceptibility locus to 1p22.

Authors:  Elizabeth Gillanders; Suh-Hang Hank Juo; Elizabeth A Holland; MaryPat Jones; Derek Nancarrow; Diana Freas-Lutz; Raman Sood; Naeun Park; Mezbah Faruque; Carol Markey; Richard F Kefford; Jane Palmer; Wilma Bergman; D Timothy Bishop; Margaret A Tucker; Brigitte Bressac-de Paillerets; Johan Hansson; Mitchell Stark; Nelleke Gruis; Julia Newton Bishop; Alisa M Goldstein; Joan E Bailey-Wilson; Graham J Mann; Nicholas Hayward; Jeffrey Trent
Journal:  Am J Hum Genet       Date:  2003-07-03       Impact factor: 11.025

Review 4.  Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium.

Authors:  R F Kefford; J A Newton Bishop; W Bergman; M A Tucker
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

5.  Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.

Authors:  H Tsao; X Zhang; K Kwitkiwski; D M Finkelstein; A J Sober; F G Haluska
Journal:  Arch Dermatol       Date:  2000-09

6.  CDKN2A germline mutations in familial pancreatic cancer.

Authors:  Detlef K Bartsch; Mercedes Sina-Frey; Sven Lang; Anja Wild; Berthold Gerdes; Peter Barth; Ralf Kress; Robert Grützmann; Mario Colombo-Benkmann; Andreas Ziegler; Stephan A Hahn; Matthias Rothmund; Harald Rieder
Journal:  Ann Surg       Date:  2002-12       Impact factor: 12.969

7.  Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.

Authors:  David M Euhus; Kristin C Smith; Linda Robinson; Amy Stucky; Olufunmilayo I Olopade; Shelly Cummings; Judy E Garber; Anu Chittenden; Gordon B Mills; Paula Rieger; Laura Esserman; Beth Crawford; Kevin S Hughes; Connie A Roche; Patricia A Ganz; Joyce Seldon; Carol J Fabian; Jennifer Klemp; Gail Tomlinson
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

8.  Familial melanoma, pancreatic cancer and germline CDKN2A mutations.

Authors:  Alisa M Goldstein
Journal:  Hum Mutat       Date:  2004-06       Impact factor: 4.878

9.  Geographical variation in the penetrance of CDKN2A mutations for melanoma.

Authors:  D Timothy Bishop; Florence Demenais; Alisa M Goldstein; Wilma Bergman; Julia Newton Bishop; Brigitte Bressac-de Paillerets; Agnès Chompret; Paola Ghiorzo; Nelleke Gruis; Johan Hansson; Mark Harland; Nicholas Hayward; Elizabeth A Holland; Graham J Mann; Michela Mantelli; Derek Nancarrow; Anton Platz; Margaret A Tucker
Journal:  J Natl Cancer Inst       Date:  2002-06-19       Impact factor: 13.506

10.  Prospective risk of cancer in CDKN2A germline mutation carriers.

Authors:  A M Goldstein; J P Struewing; M C Fraser; M W Smith; M A Tucker
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

View more
  9 in total

1.  Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.

Authors:  Nicholas J Taylor; Nandita Mitra; Lu Qian; Marie-Françoise Avril; D Timothy Bishop; Brigitte Bressac-de Paillerets; William Bruno; Donato Calista; Francisco Cuellar; Anne E Cust; Florence Demenais; David E Elder; Anne-Marie Gerdes; Paola Ghiorzo; Alisa M Goldstein; Thais C Grazziotin; Nelleke A Gruis; Johan Hansson; Mark Harland; Nicholas K Hayward; Marko Hocevar; Veronica Höiom; Elizabeth A Holland; Christian Ingvar; Maria Teresa Landi; Gilles Landman; Alejandra Larre-Borges; Graham J Mann; Eduardo Nagore; Håkan Olsson; Jane M Palmer; Barbara Perić; Dace Pjanova; Antonia L Pritchard; Susana Puig; Helen Schmid; Nienke van der Stoep; Margaret A Tucker; Karin A W Wadt; Xiaohong R Yang; Julia A Newton-Bishop; Peter A Kanetsky
Journal:  J Am Acad Dermatol       Date:  2019-02-05       Impact factor: 11.527

2.  Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma.

Authors:  V Nikolaou; X Kang; A Stratigos; H Gogas; M C Latorre; M Gabree; M Plaka; C N Njauw; K Kypreou; I Mirmigi; I Stefanaki; H Tsao
Journal:  Br J Dermatol       Date:  2011-11-02       Impact factor: 9.302

3.  Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.

Authors:  Alisa M Goldstein; May Chan; Mark Harland; Nicholas K Hayward; Florence Demenais; D Timothy Bishop; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarra; William Bruno; Donato Calista; Lisa A Cannon Albright; Valerie Chaudru; Agnes Chompret; Francisco Cuellar; David E Elder; Paola Ghiorzo; Elizabeth M Gillanders; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M MacKie; Veronica Magnusson; Graham J Mann; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

4.  Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.

Authors:  F Demenais; H Mohamdi; V Chaudru; A M Goldstein; J A Newton Bishop; D T Bishop; P A Kanetsky; N K Hayward; E Gillanders; D E Elder; M F Avril; E Azizi; P van Belle; W Bergman; G Bianchi-Scarrà; B Bressac-de Paillerets; D Calista; C Carrera; J Hansson; M Harland; D Hogg; V Höiom; E A Holland; C Ingvar; M T Landi; J M Lang; R M Mackie; G J Mann; M E Ming; C J Njauw; H Olsson; J Palmer; L Pastorino; S Puig; J Randerson-Moor; M Stark; H Tsao; M A Tucker; P van der Velden; X R Yang; N Gruis
Journal:  J Natl Cancer Inst       Date:  2010-09-28       Impact factor: 13.506

Review 5.  Selection criteria for genetic assessment of patients with familial melanoma.

Authors:  Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2009-10       Impact factor: 11.527

6.  Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO.

Authors:  Wenyi Wang; Kristin B Niendorf; Devanshi Patel; Amanda Blackford; Fabio Marroni; Arthur J Sober; Giovanni Parmigiani; Hensin Tsao
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

Review 7.  Genetic risk factors for melanoma.

Authors:  Kathrine Damm Meyle; Per Guldberg
Journal:  Hum Genet       Date:  2009-07-08       Impact factor: 4.132

8.  Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.

Authors:  Ching-Ni Jenny Njauw; Ivana Kim; Adriano Piris; Michele Gabree; Michael Taylor; Anne Marie Lane; Margaret M DeAngelis; Evangelos Gragoudas; Lyn M Duncan; Hensin Tsao
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

9.  CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.

Authors:  Fani Karagianni; Ching-Ni Njauw; Katerina P Kypreou; Aravela Stergiopoulou; Michaela Plaka; Dorothea Polydorou; Vasiliki Chasapi; Leontios Pappas; Ioannis A Stratigos; Gregory Champsas; Peter Panagiotou; Helen Gogas; Evangelos Evangelou; Hensin Tsao; Alexander J Stratigos; Irene Stefanaki
Journal:  Acta Derm Venereol       Date:  2018-10-10       Impact factor: 4.437

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.